Oncology Pipeline

Tumor Type: Breast Cancer; Gastrointestinal Cancers; Genitourinary Cancers; Gynecologic Cancers; Head and Neck Cancers; Hematology; Lung Cancer; Melanoma; Solid Tumors; Thyroid Cancer

Phase I

- **CD137 switch antibody** (CHU)[b] — Solid Tumors
- **Codrituzumab** (CHU)[b] — Gastrointestinal (HCC)
- **HLA-A2-WT1 x CD3** (RG6007) — Hematology (AML)
- **Glofitamab (Anti-CD20 CD3 TCB)** (RG6026) — Hematology
- **Tiragolumab (anti-TIGIT)** (MTIG7192A, RG6058) — Hematology, Solid Tumors
- **CD19-4-1BBL** (RG6076) — Hematology
- **TLR7 agonist (4)** (RG6115) — Gastrointestinal (HCC)
- **Cevostamab (FcRH5 x CD3)** (RG6160) — Hematology (MM)
- **Giredestrant (SERD)** (RG6171) — Breast
- **Autogene cevumeran (iNeST)** (RG6180)[a] — Solid Tumors
- **Belvarafenib (pan-RAF inhibitor)** (RG6185) — Solid Tumors
- **FAP-CD40** (RG6189) — Solid Tumors
- **HER2 x CD3** (RG6194) — Breast
- **TYRP1 x CD3** (RG6232) — Melanoma
- **NME** (RG6234) — Hematology (MM)
- **PD1-IL2v** (RG6279) — Solid Tumors
- **NME** (RG6286) — Gastrointestinal (CRC)
- **MAGE-A4 ImmTAC** (RG6290)[e] — Solid Tumors
- **Anti-CD25** (RG6292) — Solid Tumors
- **IL15/IL15Ra-Fc** (RG6323)[c] — Solid Tumor
- **KRAS G12C** (RG6330) — Solid Tumors
- **SHP2i** (RG6433) — Solid Tumors
- **Ipatasertib (AKT inhibitor)** (RG7440)[d] — Genitourinary (PC)
- **Atezolizumab▼ (anti–PD-L1 MAb)** (RG7446) — Lung (SCLC), Solid Tumors
- **Venetoclax▼ (BCL-2 inhibitor)** (ABT-199, RG7601)[h] — Hematology (AML, MDS)
- **Cibisatamab (CEA x CD3)** (RG7802) — Solid Tumors
- **FAP 4-1BBL** (RG7827) — Solid Tumors
- **Mosunetuzumab (Anti-CD20/CD3 TDB)** (RG7828) — Hematology
- **PBMC vaccine** (SQZ)[f] — Solid Tumors
- **Glypican-3 x CD3** (CHU)[b] — Solid Tumors

Phase II

- **Tiragolumab (anti-TIGIT)** (MTIG7192A, RG6058) — Head and Neck (SCCHN), Gynecologic (CC), Lung (NSCLC)
- **Anti-PD-1 x LAG3** (RG6139) — Solid Tumors
- **Giredestrant (SERD)** (RG6171) — Breast
- **Autogene cevumeran (iNeST)** (RG6180)[a] — Melanoma
- **Venetoclax▼ (BCL-2 inhibitor)** (ABT-199, RG7601)[h] — Hematology (MM)
- **PD-1 x TIM3** (RG7769) — Solid Tumors
- **rhPTX-2 (PRM-151)** (RG6354) — Hematology (myelofibrosis)
- **Oncolytic Type 5 adenovirus** (CHU)[b] — Gastrointestinal (EC)

Phase III

- **Trastuzumab emtansine (T-DM1)** (RG3502) — Breast
- **Glofitamab (Anti-CD20 CD3 TCB)** (RG6026) — Hematology (DLBCL)
- **Tiragolumab (anti-TIGIT)** (MTIG7192A, RG6058) — Lung (SCLC, NSCLC), Gastrointestinal (EC)
- **Inavolisib (PI3K alpha inhibitor)** (RG6114) — Breast
- **Giredestrant (SERD)** (RG6171) — Breast
- **Ipatasertib (AKT inhibitor)** (RG7440)[d] — Genitourinary (PC)
- **Mosunetuzumab (CD20 x CD3)** (RG7828) — Hematology (FL)
- **Polatuzumab Vedotin** (RG7596) — Hematology (DLBCL)
- **Venetoclax▼ (BCL-2 inhibitor)** (ABT-199, RG7601)[h] — Hematology (MM, MDS)
- **Atezolizumab▼ (anti–PD-L1 MAb)** (RG7446) — Genitourinary (RCC, BC), Gastrointestinal (HCC), Head and Neck (SCCHN), Lung (NSCLC), Breast
- **Alectinib (ALK inhibitor)** (RG7853) — Lung (NSCLC)
- **Entrectinib** (RG6268) — Lung (NSCLC)

Filings / Registrations

- **Pralsetinib (RET inhibitor)** (RG6396)[g]
  - RET Fusion-Positive Non-Small Cell Lung Cancer (approved in US in 2020, see label for prescribing information; filed in EU)
  - RET-Mutant Medullary Thyroid Cancer (approved in US in 2020, see label for prescribing information)
- **Atezolizumab▼ (anti–PD-L1 MAb)** (RG7446)
  - Adjuvant treatment of PD-L1-positive Non-Small Cell Lung Cancer (filed in US)

These compounds and their uses are investigational and have not been approved by the US Food and Drug Administration or the European Medicines Agency. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in preclinical studies to humans is currently being evaluated.

The Oncology Pipeline information is consistent with Roche's Half Year Results 2021 presentation (as of Jul 22, 2021). Available at https://www.roche.com/irp210722-a.pdf. Accessed Jul 30, 2021.

AKT=protein kinase B; AML=acute myeloid leukemia; BC=bladder cancer; CC=cervical cancer; CD=cluster of differentiation; CHU=Chugai; CRC=colorectal cancer; DLBCL=diffuse large B cell lymphoma; EC=esophageal cancer; FAP=fibroblast activation protein; FcRH5=Fc receptor homolog 5; HCC=hepatocellular carcinoma; HER2=human epidermal growth factor receptor 2; HLA-A2-WT1=human leukocyte antigen-A2 Wilms tumor protein 1; Ig=immunoglobulin; IL2v=interleukin-2 variant; ImmTAC=immune mobilizing monoclonal TCRs against cancer; iNeST=Individualized Neoantigen-Specific Immunotherapy; ITIM=immunoreceptor tyrosine-based inhibition motif; KRAS G12C=Kirsten rat sarcoma viral oncogene homolog G12C mutation; LAG3=lymphocyte-activation gene 3; MAb=monoclonal antibody; MAGE-A4=melanoma-associated antigen A4; MDS=myelodysplastic syndrome; MM=multiple myeloma; NHL=non-Hodgkin's lymphoma; NME=new molecular entity; NSCLC=non-small cell lung cancer; PC=prostate cancer; PBMC=peripheral blood mononuclear cell; PC=prostate cancer; PD-1=programmed cell death protein 1; PD-L1=programmed death-ligand 1; PI3K=phosphoinositide 3-kinase; RCC=renal cell carcinoma; RET=rearranged during transfection; SCCHN=squamous cell carcinoma of head and neck; SCLC=non-small cell lung cancer; SERD=selective estrogen receptor degrader; TCR=T-cell receptor; TIGIT=T-cell immunoreceptor with Ig and ITIM domains; TIM3=T-cell immunoglobulin mucin-3; TLR7=toll-like receptor 7; TYRP1=tyrosinase-related protein 1.

[a]Developed in collaboration with BioNTech.
[b]Developed in collaboration with Chugai.
[c]Developed in collaboration with Xencor.
[d]Developed in collaboration with Array BioPharma.
[e]Developed in collaboration with Immunocore.
[f]Developed in collaboration with SQZ Biotechnology.
[g]Developed in collaboration with Blueprint Medicines.
[h]Venetoclax is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the US and by AbbVie outside of the U.S.

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Please report suspected adverse reactions to the National Health Authority in your country and/or Roche Safety contact in your country (www.roche.com and select your country).